Home / 2616.HK : HKSE

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does 2616.HK make money? Does 2616.HK have pricing power? What's the Earnings Whisper? Will 2616.HK profit more as the business scales? What is 2616.HK's management track record? Is 2616.HK's current price justified?

CStone Pharmaceuticals

HKD 5.97 +$0.63 (+11.89%)

HKSE · 14 Sep 2026 08:08 UTC

Previous Close

HKD 5.79

Day Range

HKD 5.58HKD 6.1

Year Range

HKD 4.01HKD 10.54

Market Cap

9.55B

AVG Volume

10.37M

Trailing/Forward PE

-18.93/2.49

PEG ratio

0.02

Dividend Yield

Next Earnings Date

2027-04-01

Primary Exchange

Hong Kong Stock Exchange

Revenue (CNY)

2616.HK Revenue (CNY) by quarter
Period	Revenue (CNY)
26 Q2	202.27M
25 Q4	220.13M
25 Q2	24.73M
24 Q4	153.04M
24 Q2	254.16M
23 Q4	202.37M
23 Q2	261.47M
22 Q4	219.6M
22 Q2	261.76M
21 Q4	164.27M

Net Income (CNY)

2616.HK Net Income (CNY) by quarter
Period	Net Income (CNY)
26 Q2	-248.8M
25 Q4	-166.82M
25 Q2	-135.09M
24 Q4	-106.91M
24 Q2	15.7M
23 Q4	-158.01M
23 Q2	-209.23M
22 Q4	-541.11M
22 Q2	-361.57M
21 Q4	-1.15B

Operating Income (CNY)

2616.HK Operating Income (CNY) by quarter
Period	Operating Income (CNY)
26 Q2	-232.51M
25 Q4	-155.47M
25 Q2	-138.58M
24 Q4	-102.42M
24 Q2	-3.66M
23 Q4	-351.6M
23 Q2	-253.97M
22 Q4	-533.39M
22 Q2	-378.75M
21 Q4	-1.08B

EBITDA (CNY)

2616.HK EBITDA (CNY) by quarter
Period	EBITDA (CNY)
26 Q2	-210.6M
25 Q4	-132.82M
25 Q2	-133.1M
24 Q4	-83.52M
24 Q2	3.22M
23 Q4	-342.38M
23 Q2	-244.26M
22 Q4	-526.07M
22 Q2	-369.34M
21 Q4	-1.07B

Cash Flows (CNY)

2616.HK Cash Flows (CNY) by quarter
Period	Cash Flows (CNY)
26 Q2	0
25 Q4	-56.03M
25 Q2	-296.81M
24 Q4	-156.05M
24 Q2	-187.13M
23 Q4	-248.03M
23 Q2	-340.83M
22 Q4	-165.93M
22 Q2	-444.81M
21 Q4	-702.33M

EPS (CNY)

2616.HK EPS (CNY) by quarter
Period	EPS (CNY)
26 Q2	-0.16
25 Q4	-0.11
25 Q2	-0.1
24 Q4	-0.08
24 Q2	0.01
23 Q4	-0.12
23 Q2	-0.17
22 Q4	-0.46
22 Q2	-0.3
21 Q4	-0.98

Expenses (CNY)

2616.HK Expenses (CNY) by quarter
Period	Expenses (CNY)
26 Q2	322.87M
25 Q4	299.5M
25 Q2	92.18M
24 Q4	170.55M
24 Q2	175.69M
23 Q4	502.47M
23 Q2	407.4M
22 Q4	641.34M
22 Q2	549.19M
21 Q4	1.24B

Cash & Debt (CNY)

2616.HK Cash & Debt (CNY) by quarter
Period	Cash & Debt (CNY)
26 Q2	1.56B
25 Q4	919.09M
25 Q2	690.1M
24 Q4	672.94M
24 Q2	857.65M
23 Q4	1.05B
23 Q2	1.03B
22 Q4	1.04B
22 Q2	1.2B
21 Q4	1.73B

Debt ratios

2616.HK Debt ratios by quarter
Period	Debt ratios
26 Q2	2.15
25 Q4	1.65
25 Q2	0.54
24 Q4	0.48
24 Q2	0.47
23 Q4	0.46
23 Q2	0.37
22 Q4	0.28
22 Q2	0.38
21 Q4	0.53

Margins

2616.HK Margins by quarter
Period	Margins
26 Q2	44.68%
25 Q4	65.43%
25 Q2	-187.64%
24 Q4	44.51%
24 Q2	67.68%
23 Q4	74.55%
23 Q2	58.68%
22 Q4	49.79%
22 Q2	64.58%
21 Q4	53.97%

Return on Capital

2616.HK Return on Capital by quarter
Period	Return on Capital
26 Q2	-19.25%
25 Q4	-27.04%
25 Q2	-42.88%
24 Q4	-29.38%
24 Q2	3.36%
23 Q4	-34.59%
23 Q2	-34.66%
22 Q4	-120.43%
22 Q2	-38.04%
21 Q4	-94.97%

Shares Outstanding

2616.HK Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	1.52B
25 Q4	1.46B
25 Q2	1.29B
24 Q4	1.28B
24 Q2	1.57B
23 Q4	1.27B
23 Q2	1.23B
22 Q4	1.17B
22 Q2	1.17B
21 Q4	1.17B

Book Value Per Share (CNY)

2616.HK Book Value Per Share (CNY) by quarter
Period	Book Value Per Share (CNY)
26 Q2	0.85
25 Q4	0.42
25 Q2	0.24
24 Q4	0.28
24 Q2	0.3
23 Q4	0.36
23 Q2	0.49
22 Q4	0.38
22 Q2	0.82
21 Q4	1.03

Total Assets (CNY)

2616.HK Total Assets (CNY) by quarter
Period	Total Assets (CNY)
26 Q2	2.06B
25 Q4	1.36B
25 Q2	1.19B
24 Q4	1.39B
24 Q2	1.53B
23 Q4	1.66B
23 Q2	1.66B
22 Q4	1.64B
22 Q2	2.01B
21 Q4	2.27B

Free Cash Flow Yield

2616.HK Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-9.61%
Sep 26	-8.98%
Aug 26	-9.42%
Aug 26	-10.3%
Aug 26	-9.63%
Aug 26	-10.52%
Jul 26	-12.79%
Jul 26	-11.93%
Jul 26	-12.15%
Jul 26	-10.43%
Jul 26	-10.16%
Jun 26	-12.45%
Jun 26	-11.9%
Jun 26	-11.81%
Jun 26	-11.72%
May 26	-6.85%
May 26	-6.84%
May 26	-6.76%
May 26	-6.49%
Apr 26	-5.87%
Apr 26	-5.63%
Apr 26	-5.41%
Apr 26	-5.42%
Apr 26	-5.79%
Mar 26	-9.39%
Mar 26	-11.46%
Mar 26	-11.02%
Mar 26	-11.77%
Feb 26	-11.79%
Feb 26	-12.63%
Feb 26	-13.19%
Feb 26	-15.3%
Jan 26	-14.45%
Jan 26	-13.68%
Jan 26	-12.64%
Jan 26	-13.32%
Jan 26	-14.4%
Dec 25	-13.52%
Dec 25	-12.67%
Dec 25	-12.44%
Dec 25	-13.4%
Nov 25	-12.43%
Nov 25	-13.57%
Nov 25	-12.43%
Nov 25	-13.88%
Oct 25	-12.04%
Oct 25	-11.92%
Oct 25	-10.92%
Oct 25	-11.07%
Oct 25	-9.54%
Sep 25	-10.69%
Sep 25	-9.38%
Sep 25	-7.97%
Sep 25	-6.47%
Aug 25	-7.42%
Aug 25	-8.26%
Aug 25	-8.57%
Aug 25	-11.39%
Aug 25	-11.79%
Jul 25	-10.64%
Jul 25	-12.15%
Jul 25	-14.91%
Jul 25	-15.41%
Jun 25	-18.89%
Jun 25	-19.52%
Jun 25	-17.42%
Jun 25	-20.38%
May 25	-20.07%
May 25	-22.49%
May 25	-27.66%
May 25	-28.63%
May 25	-26.83%
Apr 25	-27.27%
Apr 25	-30.92%
Apr 25	-32.47%
Apr 25	-25.32%
Mar 25	-19.01%
Mar 25	-18.12%
Mar 25	-17.46%
Mar 25	-18.9%
Feb 25	-18.68%
Feb 25	-20.67%
Feb 25	-23.85%
Feb 25	-27.18%
Jan 25	-27.55%
Jan 25	-26.87%
Jan 25	-29.53%
Jan 25	-29.5%
Jan 25	-25.81%
Dec 24	-27.86%
Dec 24	-27.8%
Dec 24	-24.38%
Dec 24	-28.4%
Nov 24	-30.12%
Nov 24	-32.88%
Nov 24	-34.73%
Nov 24	-33.15%
Nov 24	-31.2%
Oct 24	-31.33%
Oct 24	-37.3%

Price to Sales

2616.HK Price to Sales by quarter
Period	Price to Sales
Sep 26	11.11
Sep 26	11.89
Aug 26	11.33
Aug 26	10.36
Aug 26	11.08
Aug 26	10.15
Jul 26	8.34
Jul 26	8.95
Jul 26	8.78
Jul 26	10.24
Jul 26	10.51
Jun 26	8.58
Jun 26	8.97
Jun 26	9.04
Jun 26	9.1
May 26	15.59
May 26	15.6
May 26	15.78
May 26	16.45
Apr 26	18.18
Apr 26	18.94
Apr 26	19.72
Apr 26	19.7
Apr 26	18.42
Mar 26	14.91
Mar 26	12.21
Mar 26	12.7
Mar 26	11.89
Feb 26	11.88
Feb 26	11.08
Feb 26	10.61
Feb 26	9.15
Jan 26	9.69
Jan 26	10.23
Jan 26	11.07
Jan 26	10.51
Jan 26	9.72
Dec 25	10.36
Dec 25	11.05
Dec 25	11.25
Dec 25	10.45
Nov 25	11.26
Nov 25	10.32
Nov 25	11.26
Nov 25	10.09
Oct 25	11.63
Oct 25	11.75
Oct 25	12.82
Oct 25	12.64
Oct 25	14.68
Sep 25	10.01
Sep 25	11.4
Sep 25	13.42
Sep 25	16.53
Aug 25	14.42
Aug 25	12.96
Aug 25	12.48
Aug 25	9.39
Aug 25	9.08
Jul 25	10.05
Jul 25	8.81
Jul 25	7.17
Jul 25	6.94
Jun 25	5.67
Jun 25	5.48
Jun 25	6.14
Jun 25	5.25
May 25	5.33
May 25	4.76
May 25	3.87
May 25	3.74
May 25	3.99
Apr 25	3.92
Apr 25	3.46
Apr 25	3.3
Apr 25	4.23
Mar 25	5.28
Mar 25	5.54
Mar 25	5.75
Mar 25	5.32
Feb 25	5.38
Feb 25	4.86
Feb 25	4.21
Feb 25	3.7
Jan 25	3.65
Jan 25	3.74
Jan 25	3.4
Jan 25	3.41
Jan 25	3.89
Dec 24	3.61
Dec 24	3.61
Dec 24	4.12
Dec 24	3.54
Nov 24	3.33
Nov 24	3.05
Nov 24	2.89
Nov 24	3.03
Nov 24	3.22
Oct 24	3.21
Oct 24	2.69

Price to Book

2616.HK Price to Book by quarter
Period	Price to Book
Sep 26	11.74
Sep 26	12.56
Aug 26	11.98
Aug 26	10.95
Aug 26	11.71
Aug 26	10.72
Jul 26	8.82
Jul 26	9.46
Jul 26	9.28
Jul 26	10.82
Jul 26	11.11
Jun 26	9.06
Jun 26	9.48
Jun 26	9.55
Jun 26	9.62
May 26	16.48
May 26	16.49
May 26	16.68
May 26	17.38
Apr 26	19.22
Apr 26	20.02
Apr 26	20.84
Apr 26	20.81
Apr 26	19.47
Mar 26	30.02
Mar 26	24.59
Mar 26	25.58
Mar 26	23.94
Feb 26	23.92
Feb 26	22.31
Feb 26	21.37
Feb 26	18.43
Jan 26	19.51
Jan 26	20.61
Jan 26	22.3
Jan 26	21.16
Jan 26	19.57
Dec 25	20.85
Dec 25	22.24
Dec 25	22.65
Dec 25	21.03
Nov 25	22.67
Nov 25	20.77
Nov 25	22.68
Nov 25	20.31
Oct 25	23.41
Oct 25	23.66
Oct 25	25.82
Oct 25	25.46
Oct 25	29.55
Sep 25	23.97
Sep 25	27.3
Sep 25	32.13
Sep 25	39.58
Aug 25	34.53
Aug 25	31.02
Aug 25	29.89
Aug 25	22.48
Aug 25	21.73
Jul 25	24.07
Jul 25	21.09
Jul 25	17.18
Jul 25	16.62
Jun 25	13.56
Jun 25	13.12
Jun 25	14.7
Jun 25	12.57
May 25	12.76
May 25	11.39
May 25	9.26
May 25	8.95
May 25	9.55
Apr 25	9.39
Apr 25	8.28
Apr 25	7.89
Apr 25	10.12
Mar 25	10.6
Mar 25	11.11
Mar 25	11.54
Mar 25	10.66
Feb 25	10.78
Feb 25	9.74
Feb 25	8.45
Feb 25	7.41
Jan 25	7.31
Jan 25	7.5
Jan 25	6.82
Jan 25	6.83
Jan 25	7.8
Dec 24	7.23
Dec 24	7.24
Dec 24	8.26
Dec 24	7.09
Nov 24	6.69
Nov 24	6.12
Nov 24	5.8
Nov 24	6.08
Nov 24	6.46
Oct 24	6.43
Oct 24	5.4

No video analysis for this stock yet. Request one from our team.

News: 2616.HK

prnewswire.com · 31 Aug 2026

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and

prnewswire.com · 27 Aug 2026

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and

AI Analysis

CStone Pharmaceuticals

Video analysis: 2616.HK

News: 2616.HK

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Similar companies